2009.06.11 Weekly Broadcast Email
The following updates were made to the website for the week of June 8, 2009.
Reminder: 91105 Conference Call TODAY at 10:00am EST
Call-in #: 877-339-0018 Meeting #: *7605195*
Reminders 98308: (A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia)
Telephone Contact Form reminders:
-Submission is required 4 weeks after end of study.
-Patient initials and protocol ID must be on form.
-All questions must be answered Yes or No.
-Antibiotic use within 4 weeks from date study medication was stopped must be documented, including the name of the antibiotic and the dates taken. This may be written at the bottom of the telephone contact form or in section 3 of the patient diary.
Toxicity Assessment sheet (TAS) is optional.
If any of the above is not included on previous submissions please add and resubmit to fax # 336-713-6476.
Featured Study 91105: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…
Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
-Upcoming conference call information
-Letter from the PI, Dr. Steve Rapp
-Brochure outlining recent changes
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors) only has 15 minority accrual slots open for patient accruals. We would like to see this study close by the end of the summer, so if you have patients that may be eligible for this study, please try and get them registered by then.